What we do Solara Active Pharma Sciences Limited develops and manufactures active pharmaceutical ingredients globally, catering to niche therapeutic segments with regulatory-approved manufacturing facilities. |
Founded in 2,017 |
Market share Strong global presence with exports to over 70 countries; approved by multiple international regulators enhancing market credibility. |
Problem solved Addresses the global demand for high-quality APIs in critical therapeutic areas including anti-infective and neuromuscular segments. |
Top clients or who we serve Global pharmaceutical companies across North America, Europe, Japan, South Korea, Middle East, and North Africa; primarily B2B. |
Key management Sandeep Shashikantha Rao (MD & CEO), Mohan Muthunarayanan (Whole Time Director & COO), Sarat Kumar (CFO), Pooja Jaya Kumar (Company Secretary). |
Our journey and innovations Incorporated in 2017 with six multi-product plants and two R&D centers; expanded through acquisitions and launched a greenfield facility in 2021. |
Where we operate India-based manufacturing with global distribution to over 70 countries, including regulated markets like the US and Europe. |
Top products or what we offer 80+ commercial APIs predominantly in anthelmintic, anti-malarial, anti-infective, neuromuscular, insomnia, and antipsychotic segments. |
Top brands Not branded products; portfolio includes APIs for novel oral anticoagulants, beta blockers, muscle relaxants, and niche pharmaceuticals. |
Raw materials needed Chemical raw materials and intermediates for API synthesis, sourced globally. |
Raw materials supplier Not specifically disclosed; likely sourced from global chemical suppliers. |
Recurring vs cyclical contribution Revenue driven by recurring contracts from pharmaceutical companies, with some cyclical elements based on industry demand. |
Our industry position Recognized for quality and regulatory compliance; significant footprint in regulated markets making it a key player among API manufacturers. |
Financial highlights FY 2024-25 revenue of ₹1284 crore with a net profit of ₹0.54 crore; operating profit improved significantly compared to prior year losses. |
Geographical revenue split Majority of revenue generated from domestic Indian operations with significant exports to regulated international markets. |
Order book - |
Whats driving growth Focus on cost optimization, enhanced capacity utilization, and expanding global regulatory approvals driving growth. |
Our future plans Increase manufacturing efficiencies, complete rights issue capital deployment, and expand contract development and manufacturing services. |
Our green promise - |
Our people and values Over 1,700 employees fostering a culture of compliance, innovation, and operational excellence. |
Key challenges ahead Managing profitability in a competitive API market and completing integration of strategic initiatives post capital raise. |
Interesting facts Holds multiple global regulatory approvals including USFDA, EDQM, MHRA, and PMDA ensuring broad market access. |
Risks and strategy Market volatility and regulatory changes mitigated through diversification and strong compliance adherence. |
